The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

Arnáiz, Joan Albert; Rodrigues-Silva, Christielly; Mezquida, Gisela; Amoretti, Sílvia; Cuesta, Manuel J.; Fraguas, David; Lobò, Antonio; González‐Pinto, Ana; Díaz-Caneja, M C; Corripio, Iluminada; Vieta, Eduard; Baeza, Inmaculada; Mané, Anna; García-Rizo, Clemente; Bioque, Miquel; Sáiz, Jerónimo; Bernardo, Miguel; Mas, Sergi

doi:10.1007/s00213-020-05715-5

Cited by 10 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is difficult to compare this association with previous findings due to differences in follow‐up duration or sample of patients. For example, a previous study of first‐episode olanzapine‐treated patients suggested a threshold of 23.28 ng/ml for CRW (>7%) after 2 months of olanzapine treatment 50 . A potential explanation for the gap between this threshold and the threshold adopted by us (80 ng/ml) may be the fact that our patients were not first‐episode patients and thus not antipsychotic exposure‐free.…”

Section: Discussionmentioning

confidence: 59%

“…For example, a previous study of first‐episode olanzapine‐treated patients suggested a threshold of 23.28 ng/ml for CRW (>7%) after 2 months of olanzapine treatment. 50 A potential explanation for the gap between this threshold and the threshold adopted by us (80 ng/ml) may be the fact that our patients were not first‐episode patients and thus not antipsychotic exposure‐free. Additionally, a study of chronic patients titrated up to 20 mg/day olanzapine reported a threshold for dose‐weighted plasma levels of 20.6 ng/ml for CRW after 6 weeks, 51 which is a shorter follow‐up window compared to ours.…”

Section: Discussionmentioning

confidence: 71%

See 1 more Smart Citation

Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort

Schoretsanitis

Dubath

Grosu

et al. 2022

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose-dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed-effects models. The risk of metabolic abnormalities including early weight gain (EWG) (≥5% during first month) was assessed using mixed-effects logistic regression models. In 392 olanzapine-treated patients (median age 38.0 years, interquartile range [IQR] = 26.0-53.3, median dose 10.0 mg/day, IQR = 5.0-10.0 for a median follow-up duration of 40.0 days, IQR = 20.7-112.2), weight gain was not associated with olanzapine dose (p = 0.61) although it was larger for doses versus ≤10 mg/day (2.54 AE 5.55 vs. 1.61 AE 4.51% respectively, p = 0.01). Treatment duration and co-

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 71%

Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort

Schoretsanitis

Dubath

Grosu

et al. 2022

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…The present manuscript had the objective to study the relationship between plasma concentrations of LAI atypical antipsychotics and clinical effectiveness as measured by direct (clinical) and indirect (experimental) parameters. This topic can have clinical utility to predict treatment response and prognosis of patients affected by severe mental disorders (e.g., SCZ) and treated with LAI SGAs [43].…”

Section: Discussionmentioning

confidence: 99%

The Relation between the Plasma Concentrations of Long-Acting Atypical Antipsychotics and Clinical Effectiveness in Patients Affected by Schizophrenia or Schizoaffective Disorder: A Comprehensive Overview

Capuzzi

Ceresa

Caldiroli

et al. 2021

CPD

View full text Add to dashboard Cite

: Atypical antipsychotic depot medications are currently recommended for patients with schizophrenia (SCZ) to prevent relapse and ameliorate the long-term prognosis of these patients. This review critically summarizes the available data about the association between the plasma concentrations of long-acting SecondGeneration Antipsychotics (SGAs) and the clinical effectiveness of these compounds in patients affected by SCZ or schizoaffective disorder. Our question is if the measurement of these concentrations can be helpful for clinicians in predicting treatment response and clinical stabilization of patients. Bibliographic research on the main databases was performed, and 13 studies were finally included in this review. Contrasting results were found between plasma concentrations of long-acting injectable (LAI) risperidone and clinical amelioration according to rating scale scores. Data are too scanty to draw conclusions for olanzapine and paliperidone. In contrast, despite small sample sizes, data are quite concordant in showing a relation between long-acting SGA plasma concentrations and D2 receptor occupancy. Despite the preliminary encouraging results, particularly for D2 receptor occupancy, future research with larger samples will have to confirm the clinical usefulness of measuring LAI SGA plasma concentrations to predict the clinical response of patients affected by severe mental conditions such as SCZ.

show abstract

“…The intra- and inter-day precision and relative errors were <15%. The olanzapine concentration–dose (C/D) ratio is a potential predictor of the effectiveness of the drug in patients with schizophrenia [ 19 ]. Therefore, we further investigated the relationship between the olanzapine C/D ratio and the polymorphisms of metabolizing enzymes.…”

Section: Methodsmentioning

confidence: 99%

Effects of CYP2D6 gene polymorphism on plasma concentration and therapeutic effect of olanzapine

Yang,

Liu,

2024

Heliyon

View full text Add to dashboard Cite

The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis

Cited by 10 publications

References 54 publications

Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort

Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort

The Relation between the Plasma Concentrations of Long-Acting Atypical Antipsychotics and Clinical Effectiveness in Patients Affected by Schizophrenia or Schizoaffective Disorder: A Comprehensive Overview

Effects of CYP2D6 gene polymorphism on plasma concentration and therapeutic effect of olanzapine

Contact Info

Product

Resources

About